Fate Therapeutics (FATE) PT Raised to $7 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Fate Therapeutics (FATE) PT Lowered to $6 at H.C. Wainwright Following FDA Clearing of FATE-NK100
March 20, 2017 7:36 AM EDTH.C. Wainwright lowered its price target on Fate Therapeutics (NASDAQ: FATE) to $6.00 (from $8.00) while maintaining a Buy rating following the FDA clearing of the Investigational New Drug application (IND) for FATE-NK100. Analysts expect preliminary data from the Phase 1/2 PROTECT study of Fate's lead product candidate ProTmune in mid-2017.
Analyst Shaunak Deepak commented, "With FDA clearing the Investigational New Drug application (IND) for FATE-NK100, we believe Fate made considerable progress to... More
Fate Therapeutics (FATE) Sees Strong Mid-Day Gains Amid Bullish Analyst PT Hikes
March 17, 2017 1:35 PM EDTFate Therapeutics (NASDAQ: FATE) sees intra-day momentum following earlier bullish analyst calls following results after the close and into a data-rich year ahead. BMO nearly doubled its price target to $7. Shares of FATE are up 6% on volume that is running 2x the norm.
... More